GENERATE BIOMEDICINES Business Summary

Generate Biomedicines Inc. (NASDAQ: GENB) is a clinical-stage biotechnology firm that utilizes a proprietary generative biology platform to design and develop novel protein-based therapeutics. The company generates revenue primarily through high-value strategic collaborations and licensing agreements with global pharmaceutical leaders, including Amgen and Novartis, which provide upfront payments and potential milestone-based payouts totaling up to $2.9 billion. Its business model centers on a single operating segment that integrates machine learning with high-throughput biological experimentation to "program" proteins for historically undruggable targets. Key clinical assets include GB-0895, a Phase 3 anti-TSLP monoclonal antibody for severe asthma designed for twice-yearly dosing, and GB-4362 for oncology. In the competitive landscape, Generate contends with AI-driven discovery platforms such as Recursion Pharmaceuticals (RXRX), Abcellera Biologics (ABCL), and Schrodinger (SDGR), distinguishing itself by focusing on de novo protein generation rather than traditional library screening to create optimized, long-acting biologics. Founded in 2018 by Flagship Pioneering, the company is led by Chief Executive Officer Michael Nally, a former Merck executive and CEO-Partner at Flagship with deep expertise in global vaccine commercialization. The executive team includes Co-founder and CTO Gevorg Grigoryan, a prominent protein scientist, and President and CFO Jason Silvers, a former Goldman Sachs partner. In January 2026, the firm expanded its C-suite by appointing Aarif Khakoo, formerly of Scribe and Amgen, as Chief Scientific Officer. Generate is governed by a high-profile board of directors chaired by Flagship founder Noubar Afeyan and featuring Moderna CEO Stéphane Bancel and Nobel Laureate Frances Arnold. The company is backed by significant institutional capital, including a strategic $10.4 million investment from Nvidia in May 2026, alongside major stakes held by Flagship Pioneering following its $400 million initial public offering in February 2026.